Results 131 to 140 of about 40,773 (330)
PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the low-density lipoprotein receptor [PDF]
, 2018 Aims PCSK9 loss of function genetic variants are associated with lower low-density lipoprotein cholesterol but also with higher plasma glucose levels and increased risk of Type 2 diabetes mellitus.
A. Baragetti +16 more
core +1 more source
Serum proprotein convertase subtilisin/Kexin type 9 and vascular disease in type 2 diabetic patients [PDF]
, 2023 BackgroundProprotein Convertase Subtilisin/Kexin type 9 (PCSK9) levels have been suggested as novel atherosclerotic biomarker. PCSK9 plays important roles in the pathogenesis of atherosclerosis by regulating the degradation of low-density lipoprotein ...
Andreozzi, Francesco +13 more
core +1 more source
PCSK9 acts as a key regulator of Aβ clearance across the blood–brain barrier
Cellular and Molecular Life Sciences, 2022 Despite the neurodegenerative disorder Alzheimer’s disease (AD) is the most common form of dementia in late adult life, there is currently no therapy available to prevent the onset or slow down the progression of AD.
Alexander D Mazura +7 more
semanticscholar +1 more source
Chemistry &Biodiversity, Accepted Article.Ziziphus budhensis is a species described in 2015 in Nepal poorly studied for its phytochemical composition and possible bioactivities. In this study, six extracts were obtained from Z. budhensis leaves using ultrasound assisted extraction with solvents in increasing polarity.
Samjhana Bharati +7 more
wiley +1 more source
Frontiers in Cardiovascular Medicine, 2023 Purpose of ReviewLong-term use of statins had been confirmed to cause an increase in hyperglycemic adverse events (HAEs), whose mechanism has been well understood.
Ruixing Zhang +10 more
doaj +1 more source
Sex differences in efficacy and safety of PCSK9 monoclonal antibodies:A real-world registry [PDF]
, 2023 Background and aims: Proprotein convertase subtilisin/kexin 9 monoclonal antibodies (PCSK9 mAbs) reduce low-density lipoprotein (LDL-c) with a favourable safety profile.
Galema-Boers, Annette M.H. +3 more
core +1 more source
Current Cardiology Reports, 2022 Treatment of dyslipidemia represents one of the most crucial strategies to reduce risk of atherosclerotic cardiovascular (CV) disease (ASCVD). In this review, we critically summarize our knowledge on emerging cholesterol-lowering therapy, targeting PCSK9,
N. Arnold, W. Koenig
semanticscholar +1 more source
PCSK9: Is it Fluoride for Cardiology?
JACC: Cardiovascular Interventions, 2014 ![Figure][1] When I first came to Emory in the 1960s, we had a medical school and a dental school. Now there is just the medical school. What happened to the dental school? The Emory Dental School, along with several others across the country, closed because of a reduced demand for dentists.
openaire +3 more sources
Catheterization and Cardiovascular Interventions, EarlyView.ABSTRACT Background Lipoprotein(a) [Lp(a)] is associated with increased cardiovascular risk, but its influence on plaque characteristics at optical coherence tomography (OCT) evaluation is not fully understood. Aims This study seeks to explore the impact of Lp(a) levels on plaque morphology as assessed by OCT in a very high‐risk subset of patients ...
Francesca Maria Di Muro +13 more
wiley +1 more source
Proteolytic cleavage of antigen extends the durability of an anti-PCSK9 monoclonal antibody[S]
Journal of Lipid Research, 2015 Lilly PCSK9 antibody LY3015014 (LY) is a monoclonal antibody (mAb) that neutralizes proprotein convertase subtilisin-kexin type 9 (PCSK9). LY decreases LDL cholesterol in monkeys and, unlike other PCSK9 mAbs, does not cause an accumulation of intact ...
Krista M. Schroeder +7 more
doaj